Company Encyclopedia
View More
name
Day One Biopharmaceuticals
DAWN.US
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company’s lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc.
1.907 T
DAWN.USMarket value -Rank by Market Cap -/-

Financial Score

22/11/2025 Update
C
BiotechnologyIndustry
Industry Ranking107/396
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-30.16%E
    • Profit Margin-113.53%E
    • Gross Margin88.74%A
  • Growth ScoreC
    • Revenue YoY31.11%A
    • Net Profit YoY-80.04%E
    • Total Assets YoY-14.49%E
    • Net Assets YoY-18.83%E
  • Cash ScoreC
    • Cash Flow Margin-88.08%D
    • OCF YoY31.11%A
  • Operating ScoreD
    • Turnover0.24D
  • Debt ScoreA
    • Gearing Ratio12.24%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    COO York II Acquires 12,813 Of Day One Biopharmaceuticals Inc [DAWN]

    York Charles N II, COO of Day One Biopharmaceuticals Inc, acquired 12,813 shares of the company. He filed a Form 4 with the SEC on November 18, 2025, detailing changes in ownership, including exercising 16,875 shares and surrendering 4,062 shares to cover option exercise costs and tax liabilities. His ending holdings are 294,715 shares directly.

    Reuters·
    US
    DAWN
    +2.77%
    Reuters·
    US
    DAWN
    +2.77%

    Day One Biopharmaceuticals to Join Piper Sandler 37th Annual Healthcare Conference

    Day One Biopharmaceuticals Inc. will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025. The event will be webcast live, with a replay available for 30 days. This information was originally published by Day One Biopharmaceuticals via GlobeNewswire.

    Reuters·
    US
    DAWN
    +2.77%
    Reuters·
    US
    DAWN
    +2.77%

    Officer Merendino Files To Sell 3,726 Of Day One Biopharmaceuticals Inc [DAWN]

    Officer Lauren Merendino of Day One Biopharmaceuticals Inc filed a Form 144 with the SEC to sell 3,726 shares on November 17, 2025. The sale will be brokered by Morgan Stanley Smith Barney LLC. Form 144 is required for selling restricted stock, allowing sales within 90 days of filing. The Washington Service offers insider trading analysis and data services.

    Reuters·
    US
    DAWN
    +2.77%
    Reuters·
    US
    DAWN
    +2.77%

    Strategic Acquisition of Mersana by Day One: Enhancing Pipeline and Growth Prospects

    Day One Biopharmaceuticals has acquired Mersana Therapeutics, enhancing its pipeline with a Phase 1 asset and ADC platform. This strategic move is expected to boost growth prospects and aligns with projected revenue from Ojemda. Despite significant upfront costs, the acquisition won't impact the company's cash flow valuation. The addition of Emi-Le, targeting rare cancers, strengthens Day One's position. Analysts from JonesTrading and Needham maintain a Buy rating, with price targets of $20 and $16, respectively.

    Tip Ranks·
    US
    MRSN
    -0.76%
    US
    DAWN
    +2.77%
    Tip Ranks·
    US
    MRSN
    -0.76%
    US
    DAWN
    +2.77%

    Day One Biopharmaceuticals to Acquire Mersana Therapeutics

    Day One Biopharmaceuticals has announced a definitive merger agreement to acquire Mersana Therapeutics, enhancing its portfolio with the antibody-drug conjugate emiltatug ledadotin (Emi-Le), currently in Phase 1 trials for adenoid cystic carcinoma type-1. The deal includes a tender offer of $25 per share in cash, plus potential milestone payments, totaling up to $55.25 per share, with an overall deal value of approximately $285 million.

    Reuters·
    US
    DAWN
    +2.77%
    Reuters·
    US
    DAWN
    +2.77%
    Posts
    View More